- Home
- TRNR vs GNPX Comparison
TRNR vs GNPX Comparison
Compare TRNR & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRNR
- GNPX
- Stock Information
- Founded
- TRNR 2017
- GNPX 2009
- Country
- TRNR United States
- GNPX United States
- Employees
- TRNR N/A
- GNPX N/A
- Industry
- TRNR Consumer Electronics/Appliances
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- TRNR Technology
- GNPX Health Care
- Exchange
- TRNR Nasdaq
- GNPX Nasdaq
- Market Cap
- TRNR 836.6K
- GNPX 854.2K
- IPO Year
- TRNR 2023
- GNPX 2018
- Fundamental
- Price
- TRNR $3.00
- GNPX $0.93
- Analyst Decision
- TRNR
- GNPX Strong Buy
- Analyst Count
- TRNR 0
- GNPX 1
- Target Price
- TRNR N/A
- GNPX $10.00
- AVG Volume (30 Days)
- TRNR 1.9M
- GNPX 854.6K
- Earning Date
- TRNR 11-14-2024
- GNPX 11-13-2024
- Dividend Yield
- TRNR N/A
- GNPX N/A
- EPS Growth
- TRNR N/A
- GNPX N/A
- EPS
- TRNR N/A
- GNPX N/A
- Revenue
- TRNR $3,180,000.00
- GNPX N/A
- Revenue This Year
- TRNR $1,543.45
- GNPX N/A
- Revenue Next Year
- TRNR $54.84
- GNPX N/A
- P/E Ratio
- TRNR N/A
- GNPX N/A
- Revenue Growth
- TRNR 226.82
- GNPX N/A
- 52 Week Low
- TRNR $2.50
- GNPX $0.28
- 52 Week High
- TRNR $4,760.00
- GNPX $14.40
- Technical
- Relative Strength Index (RSI)
- TRNR 36.17
- GNPX 42.61
- Support Level
- TRNR $2.85
- GNPX $0.82
- Resistance Level
- TRNR $3.40
- GNPX $0.96
- Average True Range (ATR)
- TRNR 0.32
- GNPX 0.10
- MACD
- TRNR 0.39
- GNPX -0.01
- Stochastic Oscillator
- TRNR 38.61
- GNPX 25.86
About TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.